CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $41.22, indicating a +0.12% shift from the previous trading day.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day.
2 No-Brainer Biotech Stocks to Buy Right Now
Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue to gain after that company moves into the product commercialization stage.
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET Company Participants Samarth Kulkarni - CEO Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good morning, everyone. Welcome again to TD Cowen's 45th Annual Healthcare Conference, our first day.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
Explore the exciting world of CRISPR Therapeutics (CRSP 0.69%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securities. Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes. The company is focused on easing pre-conditioning regimes and developing allogeneic and in-vivo therapies, which could exponentially increase the addressable market and drive future revenue growth.
